The global generalized anxiety disorder treatment market is expected to garner a market value of USD 1800 Million in 2023 and is expected to accumulate a market value of USD 4261.25 Million by registering a CAGR of 9% in the forecast period 2023 to 2033. Growth of the generalized anxiety disorder treatment market can be attributed to increasing prevalence of mental health disorders along with availability of numerous treatments to treat the ailment.
The market for generalized anxiety disorder treatment registered a CAGR of 5.1% in the historical period 2018 to 2022
Generalized anxiety disorder is a mental health disorder characterized by excessive and persistent worry or anxiety about various events or activities, even when there is little or no reason to worry. Generalized anxiety disorder can be a chronic condition and can significantly affect a person's daily life. There are several treatment options for generalized anxiety disorder, that includes Cognitive-behavioral therapy (CBT), Medications, relaxation techniques, lifestyle changes and support groups.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 1800 Million |
| Anticipated Forecast Value (2033) | USD 4261.25 Million |
| Projected Growth Rate (2023 to 2033) | 9% CAGR |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
According to market research and competitive intelligence provider Future Market Insights- the market for generalized anxiety disorder treatment market reflected a value of 5.1% during the historical period, 2018 to 2022.
The generalized anxiety disorder treatment market has been growing steadily over the past few years and is expected to continue to do so in the coming years. This is owing to the rising demand for mental health services and increasing government initiatives to promote mental health awareness. In addition, increasing prevalence of anxiety disorders, advances in treatment options, and growing awareness about mental health is expected to shape the landscape for generalized anxiety disorder treatment market.
Thus, the market for generalized anxiety disorder treatment market is expected to register a CAGR of 9% in the forecast period 2023 to 2033.
Growing prevalence and awareness regarding mental health accelerating market growth of generalized anxiety disorder
The prevalence of generalized anxiety disorder is increasing worldwide, which is expected to drive the demand for generalized anxiety disorder treatment. According to the World Health Organization (WHO), anxiety disorders affect approximately 3.6% of the global population.
There is a growing awareness about mental health issues, including generalized anxiety disorder, which is driving the demand for generalized anxiety disorder treatment. This is expected to further boost the generalized anxiety disorder treatment market.
There have been significant advances in the treatment options available for generalized anxiety disorder, including new medications and therapies, which are expected to drive the growth of the generalized anxiety disorder treatment market.
The increasing healthcare spending and government initiatives to improve mental health services are also expected to drive the growth of the generalized anxiety disorder treatment market.
The adoption of telemedicine and remote consultation is expected to increase the accessibility of mental health services, which will likely drive the demand for generalized anxiety disorder treatment.
Limited access to mental health services affecting overall market growth
Stigma associated with mental health issues, including generalized anxiety disorder, can be a significant barrier to seeking and receiving treatment. This can limit the growth of the generalized anxiety disorder treatment market. The cost of generalized anxiety disorder treatment, including medications and therapy, can be high, which can limit access to treatment for those who cannot afford it. This is a significant challenge, particularly in developing countries.
There is a shortage of mental health professionals, particularly in rural areas, which can limit access to treatment for those in need. A lack of awareness about generalized anxiety disorder and the available treatment options can also be a challenge. Many people may not be aware that they have generalized anxiety disorder or may not know where to seek help.
The side effects of medications used to treat generalized anxiety disorder can be significant, and some people may not tolerate them well, which can limit the effectiveness of the treatment.
Generalized anxiety disorder is often comorbid with other mental health disorders, such as depression, which can complicate treatment and make it more challenging to manage. All these factors are affecting the growth of the generalized anxiety disorder treatment market.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Presence of key players boosting implementation of generalized anxiety disorder treatment
The North America generalized anxiety disorder treatment market is expected to grow significantly in the coming years due to the increasing prevalence of generalized anxiety disorder and the growing awareness of the condition. Some of the major players in the market include pharmaceutical companies such as Pfizer Inc., Eli Lilly and Company, and GlaxoSmithKline plc, which develop and market medications used to manage symptoms of generalized anxiety disorder.
The North America generalized anxiety disorder treatment market is also impacted by the increasing demand for alternative therapies and natural remedies. As such, there has been an increase in the use of herbal supplements, mindfulness meditation, and yoga to manage symptoms of generalized anxiety disorder.
Overall, the North America generalized anxiety disorder treatment market is expected to continue to grow as more individuals seek treatment for this condition and as new treatments and therapies are developed to manage its symptoms. Thus, North America is expected to possess 47% market share for generalized anxiety disorder treatment market in 2023.
Effective and safe treatment options encouraging people to take therapies
The Asia Pacific GAD treatment market is expected to grow significantly in the coming years due to several factors, including the increasing prevalence of mental health disorders, growing awareness about mental health issues, and rising demand for effective and safe treatment options. Some of the major players in the market include pharmaceutical companies such as Pfizer Inc., GlaxoSmithKline plc, and Eli Lilly and Company, which develop and market medications used to manage symptoms of GAD.
The Asia Pacific GAD treatment market is also impacted by the increasing demand for alternative therapies and natural remedies. As such, there has been an increase in the use of herbal supplements, mindfulness meditation, and yoga to manage symptoms of GAD. Thus, Asia Pacific is expected to possess 42% market share for generalized anxiety disorder treatment market in 2023.
Multi-purpose use of antidepressants increasing its usage to treat generalized anxiety disorder
Antidepressants work by increasing the levels of certain chemicals in the brain, such as serotonin and norepinephrine, which can help to reduce anxiety symptoms. Antidepressants are often taken on a long-term basis, which means they can provide sustained relief from anxiety symptoms over time.
Unlike some other medications used to treat anxiety, such as benzodiazepines, antidepressants are not addictive, making them a safer option for long-term use. Many people with generalized anxiety disorder also experience symptoms of depression, such as low mood and lack of energy. Antidepressants can help to treat both anxiety and depression, making them a useful treatment option for people with generalized anxiety disorder who have comorbid depression.
Thus, antidepressants are expected to possess 48% market share for generalized anxiety disorder treatment market in 2023.
Key players in the generalized anxiety disorder treatment market are MindMed, VistaGen Therapeutics, Actavis, Takeda Pharmaceuticals, Bionomics, Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals Limited, Pfizer, Inc., Abbott Laboratories, Bristol-Myers Squibb and Actavis Pharmaceutical Company
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 1800 Million |
| Market Value in 2033 | USD 4261.25 Million |
| Growth Rate | CAGR of 9% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
Drug Class, Therapies, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; MEA |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Rest of Latin America, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, India, Malaysia, Singapore, Thailand, Rest of South Asia, China, Japan, South Korea, Austria, New Zealand, GCC countries, South Africa, Israel, Rest of MEA |
| Key Companies Profiled | MindMed; VistaGen Therapeutics; Actavis; Takeda Pharmaceuticals; Bionomics; Eli Lilly and Company; GlaxoSmithKline Pharmaceuticals Limited; Pfizer, Inc.; Abbott Laboratories; Bristol-Myers Squibb; Actavis Pharmaceutical Company |
| Customization | Available Upon Request |
In 2023, the market is expected to generate USD 1,800 million revenue.
The global market is poised to witness 9% CAGR through 2033.
The antidepressant segment is poised to have 48% market share in 2023.
North America market is leading with 47% of the global market size in 2023.
The overall demand in Asia Pacific is poised to be around 42% of the global demand.
| Estimated Market Size (2024E) | USD 11 billion |
|---|---|
| Projected Market Value (2034F) | USD 18.3 billion |
| Value-based CAGR (2024 to 2034) | 5.2% |
| Estimated Market Value (2022E) | USD 11.5 billion |
|---|---|
| Forecasted Market Value (2032F) | USD 16.1 billion |
| Market CAGR (2022 to 2032) | 3.4% |
| Market Value (2022) | USD 115.1 Million |
|---|---|
| Market Anticipated Forecast Value (2032) | USD 173.9 Million |
| Market Projected Growth Rate (2022 to 2032) | 3.8% |
Explore Therapy Area Insights
View Reports
Generalized Anxiety Disorder Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
